Puma Biotechnology, Inc. balance sheet

At the end of fiscal 2025, Puma Biotechnology, Inc. had total assets of $216m, total liabilities of $86.0m and shareholders' equity of $130m. It held $29.6m in cash against $22.7m of debt: net cash of $7.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Puma Biotechnology, Inc.: balance sheet, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	82	108	60	85	63	76	85	69	30	37
Receivables	10	21	29	26	33	40	48	32	54	34
Inventory	2	3	3	3	7	5	7	9	6	13
Total current assets	106	203	166	146	140	134	156	148	163	145
Total assets	166	259	235	244	227	222	231	213	216	193
Accounts payable	28	21	19	12	11	6	7	6	5	3
Total current liabilities	58	67	91	114	110	77	99	96	81	50
Short-term debt	—	—	—	14	0	0	34	45	23	0
Long-term debt	48	152	95	84	97	98	66	22	0	0
Total debt	50	155	100	100	102	102	102	102	23	0
Total liabilities	112	225	217	250	229	200	177	121	86	54
Shareholders' equity	53	34	17	−6	−2	22	53	92	130	139
Net debt (negative = net cash)	−32	47	40	15	39	26	17	33	−7	−37
Shares outstanding	38m	38m	39m	40m	41m	46m	48m	49m	50m	51m

US$ millions unless shown otherwise. Fiscal quarters.

Puma Biotechnology, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	55	32	25	26	34	54	26	34
Inventory	3	9	9	9	9	6	9	13
Total current assets	157	148	133	137	144	163	142	145
Total assets	221	213	196	195	203	216	193	193
Accounts payable	8	6	6	5	6	5	8	3
Total current liabilities	110	96	87	79	83	81	60	50
Short-term debt	45	45	45	34	34	23	11	0
Long-term debt	33	22	11	11	0	0	0	0
Total debt	78	67	56	45	34	23	11	0
Total liabilities	150	121	99	90	88	86	64	54
Shareholders' equity	71	92	97	105	115	130	128	139
Shares outstanding	49m	49m	50m	50m	50m	50m	51m	51m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IDYA vs PBYI ANAB vs PBYI PBYI vs RYTM AKBA vs PBYI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Puma Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Puma Biotechnology, Inc.